Esperion Launches New Scientific Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)
February 27, 2023 4:21 PM ESTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)
The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More
